Environmental

Jasper Therapeutics appears to have limited disclosed environmental intensity data, leaving its peer-relative footprint harder to assess than larger biotech peers with fuller sustainability reporting.

The company’s low leverage suggests a smaller balance-sheet-driven environmental risk profile than more capital-intensive peers, but this does not substitute for operational emissions disclosure.

No material environmental controversies or regulatory breaches are evident in the provided inputs, which supports a neutral-to-slightly-better position versus peers with active environmental liabilities.

As a clinical-stage biotech, its environmental exposure is typically concentrated in laboratory and supply-chain impacts, which are usually less material than manufacturing-heavy life sciences peers.

Social

Jasper’s R&D-to-revenue metric is zero in the provided data, indicating limited scale and making peer comparison on workforce and innovation-related social practices less transparent.

The absence of disclosed stock-based compensation intensity suggests less dilution-linked employee incentive pressure than peers with heavier equity compensation, though disclosure quality remains limited.

No major product-safety, labor, or community controversies are indicated in the supplied information, which avoids the social downside seen at peers with active disputes.

As a development-stage biotech, its social profile is primarily shaped by clinical-trial conduct and patient safety, but the available data do not show a clear peer-leading advantage.

Governance

Jasper’s low debt-to-equity ratio of 0.19 and net debt-to-EBITDA of 0.23 indicate comparatively restrained leverage, which reduces creditor-driven governance pressure versus more indebted peers.

The absence of elevated stock-based compensation in the provided metrics suggests less governance strain from equity dilution than peers with aggressive compensation structures.

Limited disclosure in the supplied data constrains assessment of board independence, audit quality, and shareholder rights, keeping the governance score below stronger-disclosure peers.

No severe governance controversy is indicated in the inputs, so the company appears cleaner than peers with litigation or control-related issues, but not clearly best-in-class.

Overall Score

Jasper Therapeutics ranks as a moderate ESG performer versus peers because it shows no major controversy or leverage-related governance stress, but disclosure depth is limited across all three pillars.

Score Driver: Limited ESG Disclosure And Lack Of Clear Peer-Leading Evidence